{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:32Z","timestamp":1778630432171,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtha.2024.07.001","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T17:24:47Z","timestamp":1720545887000},"page":"2745-2751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU\/mL"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-9055","authenticated-orcid":false,"given":"Bert","family":"Verbruggen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus B.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra J.C.","family":"van Velp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Polenewen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7225","authenticated-orcid":false,"given":"Paul","family":"Kn\u00f6bl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sobas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2987-281X","authenticated-orcid":false,"given":"Gary W.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.001_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.001_bib2","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.jtha.2024.07.001_bib3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0037-1615080","volume":"79","author":"Giles","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.001_bib5","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1111\/j.1538-7836.2012.04902.x","article-title":"Factor VIII inhibitors: von Willebrand factor makes a difference in\u00a0vitro and in\u00a0vivo","volume":"10","author":"Shi","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.001_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1055\/s-0029-1245111","article-title":"The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation","volume":"35","author":"Meijer","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.07.001_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1309\/AJCPMKP94CODILWS","article-title":"Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience","volume":"131","author":"Peerschke","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2024.07.001_bib8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2516.2009.02173.x","article-title":"Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia","volume":"16","author":"Favaloro","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.001_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/hae.14158","article-title":"Factor VIII\/IX inhibitor testing practices in the United Kingdom: results of a UKHCDO and UKNEQAS national survey","volume":"27","author":"Batty","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.001_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ijlh.14109","article-title":"International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors","volume":"45","author":"Meijer","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.07.001_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12799","article-title":"Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen\u2013Bethesda assay","volume":"6","author":"Ketteler","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.07.001_bib12","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.jtha.2024.07.001_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/medicina57050503","article-title":"Foundational statistical principles in medical research: sensitivity, specificity, positive predictive value, and negative predictive value","volume":"57","author":"Monaghan","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jtha.2024.07.001_bib14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1055\/s-0037-1616765","article-title":"The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors","volume":"86","author":"Verbruggen","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.001_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/ijlh.14258","article-title":"Variability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products","volume":"46","author":"Suzuki","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.07.001_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620976913","article-title":"The evaluation of APTT reagents in reference plasma, recombinant FVIII products; Kovaltry\u00ae and Jivi\u00ae using CWA, including sTF\/7FIX assay","volume":"27","author":"Wada","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2024.07.001_bib17","first-page":"724","article-title":"Factor VIII (FVIII) inhibitor testing using a validated chromogenic Bethesda assay (CBA) in HAVEN 1 (BH29884), a phase 3 trial of emicizumab in persons with hemophilia A (PwHA) with inhibitors","volume":"1","author":"Adamkewicz","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.001_bib18","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/ijlh.13384","article-title":"Validation of the\u00a0chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving emicizumab","volume":"43","author":"Miller","year":"2021","journal-title":"Int J Lab Hematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T01:53:46Z","timestamp":1739498026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624003842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1538783624003842"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.001","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU\/mL","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}